Posted in | News | Nanomaterials

Major Research Institution Approves Investigator-Initiated Study

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), a development stage company that is creating special purpose nanomaterials for viral therapy, announced today that the Institutional Review Committee of a major research institute in New York has approved an investigator-initiated in vivo study which will evaluate certain topical nanoviricide™ eye drug candidates.

This approved project is designed to study the effect of different nanoviricide™ drug candidates on herpes simplex virus (HSV) infection of the cornea. The Company will be providing the drug candidates free of charge. The principal investigator is an Associate Professor of Ophthalmology at the Albert Einstein School of Medicine. She has previously conducted an in vivo study that resulted in the demonstration of a strong clinical effect of certain nanoviricide drug candidates against adenovirus induced keratoconjunctivitis in rabbit eyes.

There are about 50,000 cases of HSV infection of the cornea in the US alone each year. It is generally caused by HSV Type I. Many of these cases lead to substantial scarring of the cornea and significantly reduced vision, which may necessitate corneal transplantation. Current treatment requires intensive monitoring and specialized procedures conducted by an ophthalmologist, often lasting several weeks to months. If the simple eye drops of an anti-herpes nanoviricide candidate produce rapid clinical resolution of the viral infection, as was found previously with adenoviral infection of the eye, such nanoviricide treatment could lead to a significant reduction in the direct health care costs pertaining to treating this disease. In addition, such an effective treatment could lead to a significant reduction in the number of corneal transplants required to treat this number one cause of corneal blindness in the developed world.

NanoViricides's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoViricides, Inc. (2019, February 14). Major Research Institution Approves Investigator-Initiated Study. AZoNano. Retrieved on April 20, 2024 from https://www.azonano.com/news.aspx?newsID=11583.

  • MLA

    NanoViricides, Inc. "Major Research Institution Approves Investigator-Initiated Study". AZoNano. 20 April 2024. <https://www.azonano.com/news.aspx?newsID=11583>.

  • Chicago

    NanoViricides, Inc. "Major Research Institution Approves Investigator-Initiated Study". AZoNano. https://www.azonano.com/news.aspx?newsID=11583. (accessed April 20, 2024).

  • Harvard

    NanoViricides, Inc. 2019. Major Research Institution Approves Investigator-Initiated Study. AZoNano, viewed 20 April 2024, https://www.azonano.com/news.aspx?newsID=11583.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.